Written by Austin Mao. Educational only, not medical advice.
What trauma-informed means
Trauma-informed care recognizes that trauma is not a personality flaw or a story to be reasoned out of. It is a physiological adaptation. The nervous system learned to protect you from a genuine threat, and that protection becomes a problem when the threat is gone but the nervous system keeps responding as if it is not.
Many research groups have studied the biology of trauma. For example, a multisite ENIGMA-PGC analysis found smaller hippocampal volume in people with PTSD (Logue et al., Biological Psychiatry 2018), though whether that is a consequence of trauma or a pre-existing risk factor is still debated. Bessel van der Kolk's clinical work argues that the body must be included in healing. That is a clinical perspective, not a proven mechanism.
The Window of Tolerance
Daniel Siegel's Window of Tolerance describes the zone of nervous system arousal within which a person can process experience. Too little arousal (hypoarousal, dissociation, numbness, collapse) and the person cannot engage. Too much (hyperarousal, panic, fight, flight, freeze) and the person cannot regulate.
For people with trauma histories, that zone is often narrower than average, and psychedelic ceremony is an intense emotional and sensory experience. In our practice, we use somatic exercises, nervous system education and preparation to work within that zone. That is our approach, not a tested protocol.
What the trials found
In the Mitchell MDMA trial for severe PTSD (n=90), 28 of 42 (67%) in the MDMA group no longer met PTSD criteria at 18 weeks vs 12 of 37 (32%) on placebo (Mitchell et al., Nature Medicine 2021; doi:10.1038/s41591-021-01336-3). In the 2021 trial of psilocybin against escitalopram for depression, the two did not differ significantly on the primary measure (Carhart-Harris et al., NEJM 2021; doi:10.1056/NEJMoa2032994).
Imaging studies report reduced default-mode network integration during the acute effects, and fMRI in patients with depression measured increased global brain integration about three weeks after treatment (Daws et al., Nature Medicine 2022; doi:10.1038/s41591-022-01744-z). In mice, a single psilocybin dose raised dendritic spine density and size by about 10% within 24 hours, persisting at one month (Shao et al., Neuron 2021). Human structural plasticity has not been measured directly.
These trials ran in research settings with clinical populations. They did not evaluate a Ceremonia retreat, and no trial has tested whether integration support lengthens benefits. How we prepare people and support them in the weeks after ceremony is our own practice. You can read how we work on our method page.
Screening is the first trauma-informed practice
Some medical and psychiatric profiles make psychedelic work risky enough that the right answer is not now, or not with us, but here is who can help. We treat screening as the first act of care, not a gate to push past. Our nurse practitioner reviews every medical intake, including psychiatric history, current medications, and recent mental health events.
When a retreat is not the right next step, I would rather say so plainly and point toward what is. Stabilization with a mental-health team can be the right first step, and it is not a failure to need it.
Common questions
- What about SSRIs, MAOIs and other medications?
- SSRIs, SNRIs and MAOIs interact with psilocybin and ayahuasca. Your prescriber leads any change, and you never stop or change a medication on your own. Tapering often takes one to two months. Our nurse practitioner reviews every medical intake.
- What if I dissociate or freeze during the experience?
- Dissociation is a protective response the nervous system learned, often early. In a ceremony with facilitators trained in trauma work, freeze states are met, not pushed through. We use grounding: orienting to the room, somatic anchors, breath and the presence of a guide. No facilitator will try to force a dissociated part open.
- What if I have had suicidal thoughts, or have them now?
- Active suicidality is a condition where a trauma-informed practice will, with care, say not now. The medicine can amplify what is already present, and that is unsafe in active crisis. Historical ideation that has been worked through in therapy is a different conversation, and our nurse practitioner decides each case. If you are in crisis right now, contact the 988 Suicide and Crisis Lifeline (US) or your local equivalent before anything else.
Key references
- Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 2021.
- Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 2021.
- Daws, R. E. et al. Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 2022.
- van der Kolk, Bessel. The Body Keeps the Score. Viking, 2014.
- Levine, Peter A. Waking the Tiger: Healing Trauma. North Atlantic Books, 1997.
- Siegel, Daniel J. The Developing Mind. Guilford Press, 1999.